Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-11-2009 | Original Article

Detection of bone metastases in patients with lung cancer: ^99mTc-MDP planar bone scintigraphy, ¹⁸F-fluoride PET or ¹⁸F-FDG PET/CT

Authors: Stefan Krüger, Andreas K. Buck, Felix M. Mottaghy, Ellen Hasenkamp, Sandra Pauls, Christian Schumann, Thomas Wibmer, Tobias Merk, Vinzenz Hombach, Sven N. Reske

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 11/2009

Abstract

Purpose

The aim of the study was to compare the diagnostic accuracy of ¹⁸F-fluorodeoxyglucose (FDG) PET/CT versus standard planar bone scintigraphy (BS) and ¹⁸F-labelled NaF (¹⁸F) PET for the detection of bone metastases (BM) in non-small cell lung cancer (NSCLC).

Methods

¹⁸F-FDG PET/CT was performed in 126 patients with NSCLC. Within 7 days BS (n = 58) or ¹⁸F PET (n = 68) was performed. ¹⁸F-FDG PET/CT, BS and ¹⁸F PET were evaluated by two experienced readers. Lesions were graded on a scale from 1 (definite BM) to 5 (degenerative lesion), and equivocal lesions were determined as indifferent (grade 3).

Results

A total of 92 patients showed degenerative lesions (grade 4/5) on PET/CT, BS or ¹⁸F PET. In 34 patients (27%) BM lesions were diagnosed (grades 1 and 2). In 13 of 18 patients BM were concordantly diagnosed with PET/CT and ¹⁸F PET. PET/CT showed more BM compared to ¹⁸F PET (53 vs 40). In one patient one osteolytic BM was false-negative on ¹⁸F PET. However, ¹⁸F PET identified four patients with BM compared to negative findings on PET/CT. Of 16 patients, 11 had concordant findings of BM on PET/CT and BS. In three patients BS was false-negative and in two patients BM were diagnosed as indifferent.

Conclusion

Integrated ¹⁸F-FDG PET/CT is superior to BS in the detection of osteolytic BM in NSCLC. Thus, PET/CT may obviate the need to perform additional BS or ¹⁸F PET in the staging of NSCLC, which significantly reduces costs.

Tritz DB, Doll DC, Ringenberg QS, Anderson S, Madsen R, Perry MC, et al. Bone marrow involvement in small cell lung cancer. Clinical significance and correlation with routine laboratory variables. Cancer 1989;63:763–6. doi:10.1002/1097-0142(19890215)63:4<763::AID-CNCR2820630426>3.0.CO;2-F.CrossRefPubMed

Bezwoda WR, Lewis D, Livini N. Bone marrow involvement in anaplastic small cell lung cancer. Diagnosis, hematologic features, and prognostic implications. Cancer 1986;58:1762–5. doi:10.1002/1097-0142(19861015)58:8<1762::AID-CNCR2820580830>3.0.CO;2-V.CrossRefPubMed

Trillet V, Revel D, Combaret V, Favrot M, Loire R, Tabib A, et al. Bone marrow metastases in small cell lung cancer: detection with magnetic resonance imaging and monoclonal antibodies. Br J Cancer 1989;60:83–8.PubMed

Schirrmeister H, Guhlmann A, Elsner K, Kotzerke J, Glatting G, Rentschler M, et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med 1999;40:1623–9.PubMed

Schirrmeister H, Guhlmann A, Kotzerke J, Santjohanser C, Kühn T, Kreienberg R, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol 1999;17:2381–9.PubMed

Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003;348:2500–7. doi:10.1056/NEJMoa022136.CrossRefPubMed

Donohoe KJ, Henkin RE, Royal HD, Brown ML, Collier BD, O’Mara RE, et al. Procedure guidelines for bone scintigraphy: 1.0. Society of Nuclear Medicine. J Nucl Med 1996;37:1903–6.PubMed

Krasnow AZ, Hellman RS, Timins ME, Collier D, Anderson T, Isitman AT. Diagnostic bone scanning in oncology. Semin Nucl Med 1997;27:107–41. doi:10.1016/S0001-2998(97)80043-8.CrossRefPubMed

Steinborn MM, Heuck AF, Tiling R, Bruegel M, Gauger L, Reiser MF. Whole-body bone marrow MRI in patients with metastatic disease to the skeletal system. J Comput Assist Tomogr 1999;23:123–9. doi:10.1097/00004728-199901000-00026.CrossRefPubMed

10.

Roland J, van den Weygaert D, Krug B, Brans B, Scalliet P, Vandevivere J. Metastases seen on SPECT imaging despite a normal planar bone scan. Clin Nucl Med 1995;20:1052–4. doi:10.1097/00003072-199512000-00002.CrossRefPubMed

11.

Sedonja I, Budihna NV. The benefit of SPECT when added to planar scintigraphy in patients with bone metastases in the spine. Clin Nucl Med 1999;24:407–13. doi:10.1097/00003072-199906000-00006.CrossRefPubMed

12.

Schirrmeister H, Glatting G, Hetzel J, Nüssle K, Arslandemir C, Buck AK, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med 2001;42:1800–4.PubMed

13.

Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 2006;47:287–97.PubMed

14.

Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998;16:3375–9.PubMed

15.

Bury T, Barreto A, Daenen F, Barthelemy N, Ghaye B, Rigo P. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 1998;25:1244–7. doi:10.1007/s002590050291.CrossRefPubMed

16.

Cheran SK, Herndon JE 2nd, Patz EF Jr. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer 2004;44:317–25. doi:10.1016/j.lungcan.2003.11.008.CrossRefPubMed

Title: Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT
Authors: Stefan Krüger
Andreas K. Buck
Felix M. Mottaghy
Ellen Hasenkamp
Sandra Pauls
Christian Schumann
Thomas Wibmer
Tobias Merk
Vinzenz Hombach
Sven N. Reske
Publication date: 01-11-2009
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 11/2009
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-009-1181-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Detection of bone metastases in patients with lung cancer: ^99mTc-MDP planar bone scintigraphy, ¹⁸F-fluoride PET or ¹⁸F-FDG PET/CT

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2009

Monitoring of systemic candidiasis by 18F-FDG PET/CT

EANM Springer Prizes 2009 Awarded

Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma

Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin’s lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin®)

A different role for FDG PET/CT in axillary lymph node staging in breast cancer

18F-FDG PET/CT in mediastinal lymph node staging of non-small-cell lung cancer in a tuberculosis-endemic country: consideration of lymph node calcification and distribution pattern to improve specificity